Drugs / DDP225
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00252993 | Nov 2005 → Mar 2006 | — | Dynogen Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT00230581 | Sep 2005 → Aug 2007 | irritable bowel syndrome | Dynogen Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DDP225 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00252993 ↗ |
| Known as | MCI-225 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095509 ↗ |
| Modality | Small molecule | — CHEMBL5095509 ↗ |